Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.55 |
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.42 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.42 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.55 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.55 |
| ▸ | PIM1 | P11309 | 3/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.55 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.55 |
| ▸ | CAMK2B | Q13554 | 3/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.55 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.55 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990938 | 0.94 | CSNK1D (0.61) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL5770544 | 0.86 | MAPK14 (0.61) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL990878 | 0.80 | MAPK14 (0.68) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL5772337 | 0.78 | MAPK14 (0.59) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL989447 | 0.75 | MAPK14 (0.51) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL17767421 | 0.74 | MAPK14 (0.56) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL990057 | 0.73 | MAPK14 (0.67) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL989496 | 0.72 | MAPK14 (0.57) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL5772307 | 0.71 | MAPK14 (0.55) | ERBB2MAPK8MAPK9CSNK1DDYRK1A | |
| SCHEMBL13143881 | 0.71 | MAPK8 (1.00) | ERBB2MAPK8MAPK9CSNK1DDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | FLT4 681/4885EGFR 256/4885KDR 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.